108.4
[1]. Antonius A Miller, et al. Phase II randomized study of dose-dense docetaxel and cisplatin every weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP8 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 008 Oct;3(10):1159-5.
[]. Aulma R Parker, et al. BNP8-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro. Mol Cancer Ther. 010 Sep;9(9):558-.
[3]. Dakshine Shanmugarajah, et al. Analysis of BNP8 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 009 Apr 1;8(10):85-.
[4]. F H Hausheer, et al. Mechanistic study of BNP8-mediated cisplatin nephroprotection: modulation of human aminopeptidase N. Cancer Chemother Pharmacol. 011 Feb;():381-91.
[5]. Frederick H Hausheer, et al. Mechanistic study of BNP8-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol. 010 Apr;5(5):941-51.
P1-P4-P0-P1-P80-P30+P35-P304+P340-P305+P351+P338-P330-P3+P34-P403+P33-P405-P501
![]()